The following resources are available to download to provide you with further information about DUPIXENT and support you in treating your patients with atopic dermatitis (AD)


DLQI Questionnaire

The DLQI questionnaire is a patient-reporting tool that consists of 10 questions measuring how their skin condition has affected their life over the last week. A high DLQI score indicates a greater impairment in quality of life.

 

Find out more

POEM Questionnaire

The POEM questionnaire is a patient-reporting tool that consists of 7 questions designed to measure the severity of AD in your patients. A high POEM score indicates a greater degree of severity.
Further information about POEM.

 

Find out more

Determining EASI

A useful tool explaining the step-by-step process of how to assess and score the severity of your patients’ AD. This will help you give them an accurate assessment and help with monitoring their AD.

 


Find out more

Patient Dosing Calendar

A useful tool explaining the step-by-step process of how to assess and score the severity of your patients’ AD. This will help you give them an accurate assessment and help with monitoring their AD.

 


Find out more

Dosing Card

A useful tool detailing the recommended dosing for adults with moderate-to-severe AD and weight-based dosing for adolescents (12 years or older) with moderate-to-severe AD and children (6–11 years) with severe AD.

 

Find out more

Patient Welcome Guide

A handbook for adults and adolescent patients with moderate-to-severe AD prescribed DUPIXENT, to ensure they understand their condition and treatment, dosing, any side effects to look out for and self-injection technique.

 

Find out more


Overview of AD

Find out more about how AD has a continuous inflammation cycle.

 


 

Find out more


Reimbursement

Learn about the reimbursement of DUPIXENT in England, Wales and Scotland.





Find out more


Events

Learn more about the upcoming events helping to transform AD for Dermatologists.





Find out more

    AD, atopic dermatitis; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; POEM, Patient Oriented Eczema Measure.

    References

    1. DUPIXENT Summary of Product Characteristics. September 2021.

MAT-IE-2101006(v6.0) | Date of preparation: February 2022